It has been reported that certain chemotherapeutics could boost antitumor immunity directly through sensitizing cancer cells to T cell killing,[45, 46] or indirectly by enhancing antigen presentation and counteracting immunosuppressive mechanisms.[46, 47] In this study, higher expression levels of HLA‐DR, CXCR3 and PD‐1 on tumor‐infiltrating Vγ9Vδ2 T cells were observed in CC patients with neoadjuvant chemotherapy than those without (Figure S8a, Supporting Information). Here, PDCD1 is linked to neoplasm.